Meningococcal Group Acwy Conjugate-Group B Vaccine (Cvx 316) Dosage

Medically reviewed by Drugs.com. Last updated on Jan 29, 2024.

Usual Adult Dose for Meningococcal Meningitis Prophylaxis

Approximately 0.5 mL IM administered as 2 doses 6 months apart

Comment:

This vaccine is approved for adults up to 25 years of age.

Use: For active immunization for the prevention of invasive disease caused by Neisseria meningitides serogroups A, B, C, W, and Y

Usual Pediatric Dose for Meningococcal Meningitis Prophylaxis

10 to less than 18 years:
Approximately 0.5 mL IM administered as 2 doses 6 months apart

Use: For active immunization for the prevention of invasive disease caused by N meningitidis serogroups A, B, C, W, and Y

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

History of severe allergic reaction (e.g., anaphylaxis) to any component of this vaccine

Safety and efficacy have not been established in patients younger than 10 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

For IM use only
Administer immediately after reconstitution.
Inform the patient of the potential benefits and risks of vaccination prior to administration.
Advise vaccine recipient to report any adverse events to their healthcare provider.

Storage requirements:

Store horizontally (to minimize resuspension time) in the refrigerator between 2C and 8C (36F and 46F) in the original carton.
Do not freeze. Discard if the vaccine is frozen.
If not used following reconstitution, store between 2C and 30C (36F and 86F) and use within 4 hours; discard if not used after 4 hours.

Reconstitution/preparation techniques:

The manufacturer product information should be consulted.

General:

Suspected adverse reactions should be reported by contacting the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 and https://vaers.hhs.gov

Patient advice: